Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
Glossary on
off
Printer Friendly Page Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04584255


Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

About the Study

NOTE: This study is no longer enrolling patients. 

This study will look at how well the drugs  (a type of known as a ) and Dostarlimab (a type of ) treat breast cancer in people with an inherited ,  or mutation. 

 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

NOTE: This study is no longer enrolling patients.